GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

CannaPharmaRx CPMD · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

-20.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$1.4m

FY2016FY2025

Net income

−$11.1m

FY2016FY2025

Free cash flow

−$794,621

FY2016FY2025

Shareholders' equity

−$30.2m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$1.4m$820,137————————
Gross profit−$2.1m−$2.9m−$65,561—−$14,364−$129,000−$129,000−$12,031——
Operating income−$3.3m−$7.6m−$1.6m−$5.2m−$2.6m−$17.6m−$3.0m−$954,000−$6,633−$1.0m
Net income−$11.1m−$9.9m$3.7m−$8.5m−$8.8m−$19.9m−$20.5m−$3.1m−$6,633−$1.0m
Diluted earnings per share-0.02-0.010.01-0.03-0.07-0.42-0.56-0.08-0.00-0.00

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$7.0m$10.8m$11.7m$5.4m$114,330$8.7m$16.0m$190,000—$1,667
Cash and short-term investments$1,804$2,156$650—$27,767$334,969$1,547$190,000——
Total liabilities$37.2m$30.6m$23.9m$22.8m$13.0m$17.5m$11.2m$964,300$964,300$959,334
Debt$20.7m$14.1m$12.9m—$9.0m$10.0m$9.3m$19,758$19,758$19,758
Shareholders' equity−$30.2m−$19.8m−$12.2m−$17.3m−$12.9m−$8.8m$4.9m−$964,300−$964,300−$957,667
Shares outstanding663m663m441m274m126m47m36m40m2m682m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$789,102−$1.7m−$2.3m−$1.4m−$2.4m−$563,573−$3.8m−$22,380−$941,136−$22,380
Capital spending−$5,519−$2−$80,634−$115,998−$6,263−$6,263−$46,937−$2,078−$46,937−$46,937
Free cash flow−$794,621−$1.7m−$2.4m−$1.6m−$2.4m−$569,836−$3.8m−$24,458−$988,073−$69,317
Dividends paid————−$39—−$2.9m———

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$276,218$627,462$138,630$656,606$231,608$335,319$482,134$312,164
Gross profit−$138,446−$409,453−$521,091−$440,000−$621,210−$503,000−$1.7m−$356,000
Operating income−$378,831−$682,343−$893,553−$935,646−$840,980−$75,342—$820,352
Net income−$1.9m−$382,021−$7.5m−$1.5m−$1.4m−$691,000−$3.7m$188,421
Diluted earnings per share-0.00-0.00-0.01-0.00-0.00-0.00-0.010.00
Cash from operations——$1.0m—————
Capital spending——−$1.0m—————
Free cash flow——$0—————
Total assets$6.9m$6.6m$7.0m$11.6m$11.5m$11.2m$10.8m$11.7m
Cash and short-term investments$555$633$1,804$927$16,975$1,208—$6,999
Debt$15.8m$16.0m$15.6m$15.0m$12.7m$11.9m—$8.6m
Shareholders' equity−$30.8m−$30.3m−$30.2m−$22.5m−$22.6m−$20.5m−$19.8m−$16.6m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-13.7%-28.2%-11.7%
Net income9.3%-11.0%-0.5%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin-230.0%———
Operating margin-503.6%———
Net margin-964.0%———

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2020FY2018FY2017
Price to earnings-0.3-0.10.0-0.0-0.0-0.0
Price to sales2.51.1————

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return222%1373%-3%-4%-96%-16%59%11845%153%52%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10-to-1 reverse split · 10 Nov 2006

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.